[White Paper] Health Technology Assessment During the COVID-19 Pandemic

The global COVID-19 pandemic currently permeates every aspect of daily life with long-lasting consequences for all sectors, including pharma and health technology assessment (HTA). Moving forward, healthcare innovators must be prepared for considerable delays to clinical trials, re-prioritization of pipeline products, and a radical shift in normal working practices. As a follow-up to their investigation on the impact of COVID-19 on integrated scientific advice procedures (See “Integrated Scientific Advice during the COVID-19 Pandemic: A Status Update on Key Programs in North America and Europe”), The Evidence Forum now focuses on another key area of risk to the commercialization of a new HTA and price negotiations.

Download the white paper here.